Last reviewed · How we verify
NCT05004805: COMBAT
COVID-19 Methylene Blue Antiviral Treatment
Phase 2 trial testing Methylene Blue in Covid19 in 24 participants. Completed in 12 December 2021.
12 December 2021
Quick facts
| Lead sponsor | Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 6 August 2021 |
| Primary completion | 12 December 2021 |
| Estimated completion | 12 December 2021 |
| Sites | 1 location across Russia |
Drugs / interventions tested
- Methylene Blue (METHYLENE BLUE) — full drug profile →
- Saline nasal spray — full drug profile →
Conditions studied
- Covid19 — all drugs for Covid19 →
Sponsor
Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences
Who can join
18 and older, any sex, with Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a pilot study of a single-center, blind, randomized, placebo-controlled, parallel-group study testing for the efficacy and safety of Methylene blue when administered topically as a 0.02% solution for nasopharyngeal and oropharyngeal irrigation in COVID-19 patients requiring hospitalization.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05004805
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Methylene Blue
Trials testing the same drug.
- NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
- NCT07494773 — Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection · Phase 1, PHASE2 · not yet recruiting
- NCT07040540 — Hemodynamic Effects of Intradermal Methylene Blue During Breast Surgery Under General Anesthesia · completed
- NCT07169487 — Adjunctive Methylene Blue for Immunotherapy-related CRS and ICANS: Phase I Study · Phase 1 · recruiting
- NCT06900140 — Adjunctive Methylene Blue in Septic Shock · Phase 3 · completed
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05004805 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences
- Last refreshed: 9 February 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05004805.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing